MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

MediWound Ltd. (MDWD) will release its financial results for Q4 and full year 2023 on March 21, 2024. A conference call and webcast will follow to discuss the results and provide updates.

Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time

YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, March 21, 2024.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates, and answer questions.

Dial-in and call details are as follows:

Conference Call & Webcast Details
Toll-Free:		1-833-630-1956
Israel:		1-80-921-2373
International:		1-412-317-1837
Webcast:		Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. MediWound specializes in the development, production and commercialization of solutions that seek to improve existing standards of care. The Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid^®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Company’s lead drug under development, EscharEx^®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant potential advantages over the $360 million dominant product and an opportunity to expand the market. MediWound’s pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a Phase I/II study.

For more information visit www.mediwound.com and follow the Company on LinkedIn and X.

MediWound Contacts:
Hani Luxenburg	Daniel Ferry
Chief Financial Officer	Managing Director
MediWound Ltd.	LifeSci Advisors, LLC
ir@mediwound.com	daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
929-588-2008

FAQ

When will MediWound Ltd. release its financial results for Q4 and full year 2023?

MediWound Ltd. will release its financial results for Q4 and full year 2023 on March 21, 2024.

What is the ticker symbol for MediWound Ltd.?

The ticker symbol for MediWound Ltd. is MDWD.

When is the conference call and webcast scheduled?

The conference call and webcast are scheduled for Thursday, March 21st at 8:30 am Eastern Time.

How can participants access the conference call and webcast?

Participants can access the call by dialing the provided telephone numbers at least 5 minutes before the start of the call.

Where can participants find the archived version of the webcast?

The archived version of the webcast will be available for replay on the Investors section of the MediWound website.